Title: 2018 ACVIM Forum Research Abstract Program: Seattle, Washington, June 14 - 15, 2018 Document date: 2018_10_25
ID: 60ceejq1_591
Snippet: Renal cysts are known to increase over time in cats with ADPKD, however, this data indicates cysts progress at different rates as determined by CT-based FCV per age and cats do not have significant increases with age in TKV. Variable FCV per age supports disease progression is individual and suggests modifiers likely influence progression. FCV can evaluate disease progression of feline ADPKD and characterize the therapeutic efficacy of drugs for .....
Document: Renal cysts are known to increase over time in cats with ADPKD, however, this data indicates cysts progress at different rates as determined by CT-based FCV per age and cats do not have significant increases with age in TKV. Variable FCV per age supports disease progression is individual and suggests modifiers likely influence progression. FCV can evaluate disease progression of feline ADPKD and characterize the therapeutic efficacy of drugs for ADPKD. One component of assessing chronic kidney disease in cats is creatinine (Cr) concentration in blood and urine measured using an automated system based on the Jaffé reaction or enzyme-based assay. Evidence from other species suggests Cr is over-estimated with the Jaffé reaction, but it is not clear if this assumption is accurate for cats. This study compared these 2 automated assay methods, with a -0.3 mg/dL correction as part of the Jaffé methodology, to measure Cr concentration in serum (SCr) and urine (UCr). Cr data was used with voided urine volume (Uvol) to calculate endogenous creatinine glomerular filtration rate (GFR) and compared to serum symmetric dimethylarginine (SDMA) concentrations.
Search related documents:
Co phrase search for related documents- SCr serum and serum symmetric dimethylarginine: 1, 2
- SCr serum and significant increase: 1
- SCr serum and symmetric dimethylarginine: 1, 2, 3, 4, 5
- SDMA concentration and serum symmetric dimethylarginine: 1
- SDMA concentration and symmetric dimethylarginine: 1, 2
- SDMA concentration and urine blood: 1
- SDMA concentration and urine blood concentration: 1
- serum symmetric dimethylarginine and symmetric dimethylarginine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- serum symmetric dimethylarginine and urine blood: 1
- significant increase and therapeutic efficacy: 1, 2, 3, 4, 5, 6, 7
- significant increase and time increase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
- significant increase and urine blood: 1, 2, 3, 4, 5
- symmetric dimethylarginine and urine blood: 1, 2
- symmetric dimethylarginine and urine blood concentration: 1
- therapeutic efficacy and time increase: 1
- time increase and urine blood: 1, 2
- UCr urine and urine blood: 1
- UCr urine SCr serum and urine blood: 1
- urine volume and voided urine volume: 1
Co phrase search for related documents, hyperlinks ordered by date